Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 16/20 | 0.78 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987280 | 0.91 | GLS (0.80) | GLS | |
| SCHEMBL14987105 | 0.91 | GLS (0.76) | GLS | |
| SCHEMBL15043796 | 0.88 | GLS (1.00) | GLSACKR3ALDH1A1HSD17B10MAPT | |
| SCHEMBL15043819 | 0.82 | GLS (1.00) | GLS | |
| SCHEMBL19920086 | 0.81 | GLS (0.78) | GLS | |
| SCHEMBL21368930 | 0.78 | GLS (0.73) | GLS | |
| SCHEMBL21368592 | 0.78 | GLS (0.53) | GLSALDH1A1HSD17B10 | |
| SCHEMBL15043773 | 0.78 | GLS (1.00) | GLS | |
| SCHEMBL21368591 | 0.77 | GLS (0.59) | GLS | |
| SCHEMBL19920088 | 0.73 | GLS (0.75) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277276-B1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| EP-2782570-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2016160980-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| WO-2015138902-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ACKR3 3813/4885ALDH1A1 639/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885ACKR3 3813/4885ALDH1A1 639/4885 |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | GLS 1/4885ACKR3 4254/4885ALDH1A1 1051/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ACKR3 3647/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.